IPSEN BIOPHARMACEUTICALS, INC. v. BECERRA

No. 23-5142.

108 F.4th 836 (2024)

IPSEN BIOPHARMACEUTICALS, INC., Appellant v. Xavier BECERRA, in his official capacity as Secretary of Health and Human Services, et al., Appellees.

United States Court of Appeals, District of Columbia Circuit.

Decided July 9, 2024.

Reissued July 25, 2024.


Attorney(s) appearing for the Case

Catherine E. Stetson argued the cause for appellant. With her on the briefs were Susan M. Cook, Marlan Golden, and Dana A. Raphael.

Urja Mittal, Attorney, U.S. Department of Justice, argued the cause for federal appellees. With her on the brief were Brian M. Boynton, Principal Deputy Assistant Attorney General, Daniel Tenny, Attorney, and Samuel R. Bagenstos, General Counsel, U.S. Department of Health & Human Services. Anna O. Mohan, Senior Counsel, U.S. Department of Justice, entered an appearance.

Brian T. Burgess argued the cause for appellee InvaGen Pharmaceuticals, Inc. With him on the brief was Gerard J. Cedrone.

Before: Wilkins, Katsas and Rao, Circuit Judges.


In 2007, the Food and Drug Administration ("FDA") approved Ipsen Biopharmaceuticals, Inc.'s application to sell Somatuline Depot as a drug product under the Federal Food, Drug, and Cosmetic Act ("FDCA"). This approval gave Somatuline Depot a period of market exclusivity, and the FDA did not authorize any competing generic...

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases